A Case Report of Hepatocellular Carcinoma 5 Years After HBsAg Loss in Chronic Hepatitis Delta: How Long Surveillance is Required?

Ann Hepatol. 2017 Jul-Aug;16(4):630-632. doi: 10.5604/01.3001.0010.0314.

Abstract

Background: Hepatitis delta virus infection occurs as acute co-infection or as superinfection in patients with preexisting chronic hepatitis B. Chronic hepatitis delta leads to more severe disease than chronic hepatitis B, with more rapid progression of fibrosis and increased risk of hepatocelullar carcinoma.

Case report: We report a case of hepatocelullar carcinoma 5 years after spontaneous clearance of Hepatitis B surface antigen in a patient with previous chronic hepatitis delta. He had been diagnosed with acute hepatitis delta superinfection 30 years ago which evolved to chronic delta infection and subsequently development of liver cirrhosis. Despite no specific antiviral treatment, he lost HBsAg persistently with later regression of cirrhosis.

Conclusions: In patients with cirrhosis due to chronic hepatitis delta who cleared HBsAg with improvement of liver fibrosis by non invasive techniques, it remains unknown how long hepatocelullar carcinoma surveillance has to be maintained.

Keywords: HBsAg clearance.; Hepatitis B; Hepatitis D; Hepatocellular carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Biomarkers / blood
  • Bone Neoplasms / secondary
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / secondary
  • Carcinoma, Hepatocellular / virology*
  • Cell Transformation, Viral
  • Disease Progression
  • Hepatitis B Surface Antigens / blood*
  • Hepatitis B, Chronic / blood
  • Hepatitis B, Chronic / diagnosis
  • Hepatitis B, Chronic / virology*
  • Hepatitis D, Chronic / blood
  • Hepatitis D, Chronic / diagnosis
  • Hepatitis D, Chronic / virology*
  • Humans
  • Liver Cirrhosis / virology
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / pathology
  • Liver Neoplasms / virology*
  • Male
  • Middle Aged
  • Niacinamide / analogs & derivatives
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use
  • Risk Factors
  • Sorafenib
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Biomarkers
  • Hepatitis B Surface Antigens
  • Phenylurea Compounds
  • Niacinamide
  • Sorafenib